-
Wedbush Reiterates Neutral and PT of $25 on Cepheid
Tuesday, July 19, 2011 - 9:21am | 54Wedbush reiterated its Neutral rating on Cepheid (NASDAQ: CPHD). At the same time, the rating agency left its price target on the company's stock unchanged at $25. On Monday, CPHD closed the day at $31.13. Its shares added 0.22% to their value in today's pre-market trading to stand around $31.20.
-
Citi Updates On BIIB
Tuesday, July 19, 2011 - 9:12am | 100Citi has issued a company update on Biogen Idec Inc (NASDAQ: BIIB) and its Gilenya sales. Accrding to the report, "20,000 patients have been exposed to Gilenya, 13,000 of which on commercial drug, (11,000 US and 2,000 EU). 7,000 are in clinical trials with 2,000 patients who have been on treatment...
-
Bank of America Initiates Ariad Pharmaceuticals At Neutral, $14 PO
Tuesday, July 19, 2011 - 7:43am | 26Bank of America has initiated coverage on Ariad Pharmaceuticals (NASDAQ: ARIA) with a Neutral rating and $14 price objective.
-
Support Held 07-18-2011
Monday, July 18, 2011 - 5:58pm | 1009Cusick's Corner Support held, 1295 on the S&Ps, and we finished the day above 1300 which is the psychological support, bringing this index, followed by the other majors, above the mid-term support of their 50-day moving averages. Tomorrow the market will focus on the Housing Starts and Permits...
-
Eli Lilly & Earnings Preview: Analysts Predict Higher Earnings Over Prior Quarter
Monday, July 18, 2011 - 2:55pm | 560It's time to get ready for Eli Lilly & (NYSE: LLY) earnings! Don't be caught off-guard: The company releases its next round of earnings this Thursday, July 21, 2011. Wondering what to expect from this Thursday's announcement? Don't worry. Here's your essential guide to Eli Lilly &'s...
-
Icagen Setting Up to Break Out
Monday, July 18, 2011 - 2:32pm | 106Shares of Icagen (NASDAQ: ICGN) are trading higher on the session by 8.61%, at $8.07. The stock has been spiking higher and higher on takeover chatter for the past month and it looks like shares could make another leap higher very soon. Icagen's most recent high is at $8.20. Shares are inching...
-
Alkermes Forecasts 2012 Pro Forma Revenues of $460M to $480M
Monday, July 18, 2011 - 2:07pm | 201Alkermes (NASDAQ: ALKS) will provide expanded financial expectations for Alkermes plc. Revenues: In fiscal year 2012, the company expects pro forma revenues to grow at a single-digit rate to a range of $460 million to $480 million. Pro forma revenues of the combined companies on a trailing 12-...
-
WANTED: Buyers 07-18-2011
Monday, July 18, 2011 - 1:26pm | 1059Cusick's Corner Buyers Wanted. The market cannot find a bid and sliced through support, 1300 on the S&Ps, and into the midday traders are waiting to see if a bid shows up in any segment other then bonds. With the Moody's news, battle on Capitol Hill, and continued EU debt risk, the shorts are...
-
Pharma Stock News; BioSante Pharmaceuticals Announces Management Team Addition
Monday, July 18, 2011 - 12:13pm | 1056LINCOLNSHIRE, Ill. - July 18, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), today announced the appointment of Sandra Croak-Brossman, MS, Ph.D., as Vice President, Regulatory Affairs and Quality Assurance, and Patricia M. Adams, MS as Vice President, Human...
-
J.P. Morgan Overweight On Gilead Sciences
Monday, July 18, 2011 - 11:59am | 206J.P. Morgan Chase & Co. is out with a research report on Gilead Sciences (NASDAQ: GILD) and it has an Overweight rating and a $45 price target on shares. In a note to clients, J.P. Morgan Chase & Co. writes, "The International AIDS Society (IAS) meeting in Rome is under way, and longer-...
-
Wedbush Reiterates Outperform On Cubist Pharmaceuticals After Earnings
Monday, July 18, 2011 - 11:48am | 137Wedbush Securities is out with a research report on Cubist Pharmaceuticals (NASDAQ: CBST) after it reported earnings. It has an Outperform rating and a $40 price target on shares. In a note to clients, Wedbush Securities writes, "Reiterating our OUTPERFORM rating and our 12-month price target of...
-
Winners and Losers as of 10:55AM
Monday, July 18, 2011 - 10:56am | 262Winners: Walter Energy (NYSE: WLT) is trading up roughly 6.90% near $118.5 after Citigroup initiated coverage with a Buy rating. First Majestic Silver (NYSE: AG) is trading up roughly 5% near $23.70 as the price of silver has risen over 2%. Greenhill & Co (NYSE: GHL) is trading up over 4.70...
-
UPDATE: Nabi Biopharmaceuticals Down Nearly 70% on Disappointing Phase 3 Results
Monday, July 18, 2011 - 10:30am | 43Nabi Biopharmaceuticals (NASDAQ: NABI) is down nearly 70% on disappointing phase 3 results this morning. The company's NicVAX phase III clinical trial did not meet its primary endpoint. Nabi Biopharmaceuticals is currently trading at $1.76, a loss of 68.74%.
-
NASDAQ Stocks Hitting 52-Week Highs
Monday, July 18, 2011 - 10:20am | 134Wynn Resorts Limited (NASDAQ: WYNN) shares rose 0.94% to create a new 52-week high of $164.15. WYNN is all set to report its Q2 earnings after the closing bell. Apple Inc (NASDAQ: AAPL) shares gained 1.03% to create a new 52-week high of $368.67. Apple is scheduled to report its quarterly earnings...
-
Options Brief: Gilead Sciences
Monday, July 18, 2011 - 10:16am | 73Shares of Gilead Sciences (NASDAQ: GILD) are lower on the session by 0.85%, trading at $40.65. Overall call volume is now running at 4.43x the daily average, with 9% of all calls traded being purchases on the offer. 19,059 contracts have traded on the session so far. Gilead Sciences, Inc. is a...